trending Market Intelligence /marketintelligence/en/news-insights/trending/m9V0yEJcPY_JYzm2WoOtRw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US PTO gives DelMar notice of allowance for brain cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US PTO gives DelMar notice of allowance for brain cancer drug

DelMar Pharmaceuticals Inc. received a notice of allowance from the U.S. Patent and Trademark Office for its patent application involving VAL-083, a potential brain cancer treatment.

VAL-083 is under preparation for a phase 3 clinical trial in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer.

The patent has also been granted in Australia and is being prosecuted in other international jurisdictions as part of more than 100 patent filings from 13 patent families representing claims covering VAL-083 until 2036.

DelMar expects the U.S. patent to be issued in early 2017.